Podcast
MSL Talk: Tom Caravela, Giovanni Passiatore
3 Things I wish I knew about being a MSL
Summary
In this episode, Tom Caravela welcomes Mitchell D’Rozario from Genentech Roche to share his journey into the MSL role. Mitchell provides three key insights he wishes he had known before becoming an MSL and poses thought-provoking questions to Tom. The discussion covers staying motivated and purpose-driven, exploring alternative career paths in the pharmaceutical industry, and the challenges of building relationships in a virtual environment. They also delve into the changing landscape of conferences and the importance of face-to-face interactions. The episode concludes with closing remarks, gratitude, and a request for subscription and feedback.
My guest today is Mitchell D’Rozario, Medical Science Liaison at Genentech and we discuss the 3 things he wished he knew about being an MSL.
In this episode we discuss:
- Mitchell’s background and breaking into the industry
- 3 things he wishes he had known about being an MSL
- What Tom wishes aspiring MSLs knew about the role
- What Tom looks for when screening candidates for roles
- Some red flags Tom notices often
- What keeps Mitchell on track
- What Mitchell learned in 2020 going through pandemic and how it changed him as an MSL
- His opinion of what 2021 will look like for field medical and what MSLs might expect
MSL career insights, pharmaceutical industry careers, virtual relationship building, Medical Science Liaison challenges, conference networking importance
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Giovanni Passiatore
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret